Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX)
Mexico City, DF, MX
Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-5.7% Q1'26: -10.2% (vs Q4'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+7.8% Q1'26: +6.3% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.9% Q1'26: -8.2% (vs Q4'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.4% ★ Q1'26: +19.6% (vs Q4'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.7% ★ Q1'26: +18.5% (vs Q4'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.5% ★ Q1'26: -0.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.32× Q1'26: 1.30× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 4 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
16.47B
est: 17.36B (-5.2%)
|
18.61B
est: 18.43B (+0.9%)
|
17.54B
est: 17.81B (-1.5%)
|
18.02B
17.75B – 18.23B
+1.2% YoY
|
19.98B
19.40B – 20.41B
+10.9% YoY
|
| EBITDA |
2.78B
est: 3.31B (-16.2%)
|
4.14B
est: 3.54B (+17.1%)
|
3.61B
est: 3.42B (+5.7%)
|
3.46B
3.40B – 3.50B
+1.2% YoY
|
3.83B
3.72B – 3.91B
+10.9% YoY
|
| EBIT |
2.55B
est: 3.07B (-17.0%)
|
3.78B
est: 3.24B (+16.5%)
|
3.23B
est: 3.13B (+3.1%)
|
3.17B
3.12B – 3.21B
+1.2% YoY
|
3.51B
3.41B – 3.59B
+10.9% YoY
|
| Net Income |
1.08B
est: 1.39B (-21.9%)
|
1.49B
est: 2.06B (-27.7%)
|
1.61B
est: 1.66B (-3.1%)
|
2.13B
1.80B – 2.49B
+28.2% YoY
|
2.45B
2.10B – 2.79B
+15.1% YoY
|
| SGA |
6.84B
est: 7.27B (-5.9%)
|
8.06B
est: 7.67B (+5.0%)
|
6.95B
est: 7.41B (-6.2%)
|
7.50B
7.38B – 7.58B
+1.2% YoY
|
8.31B
8.07B – 8.49B
+10.9% YoY
|
| EPS |
1.13
est: 1.42 (-20.4%)
|
1.53
est: 2.12 (-27.8%)
|
1.65
est: 1.70 (-3.2%)
|
2.18
1.85 – 2.56
+28.2% YoY
|
2.51
2.16 – 2.87
+15.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | OTG Latin America ETF OTGL | 1.20% | 260.0K | 0.95% |
| 2 | Cambria Emerging Shareholder Yield ETF EYLD | 0.96% | 8.09M | 0.65% |
| 3 | iShares MSCI Mexico ETF EWW | 0.48% | 8.97M | 0.50% |
| 4 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.12% | 53.3K | 0.54% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.08% | 1.37M | 0.58% |
| 6 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 142.6K | 0.72% |
| 7 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 117.1K | 0.74% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.03% | 111.7K | 0.33% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 133.1K | 0.55% |
| 10 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 25.1K | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alejandro Bastón Patiño | EVice President of Institutional Relations, Media, HR & Sustainability | — | male |
| Antonio Zamora Galland | Executive Vice President of Finance & Administration and Chief Financial Officer | — | — |
| Christianne Ibáñez Garcia | Head of Investor Relations | — | female |
| Daniel Suarez Neria | Investor Relations Officer | — | — |
| Efraan Tapia Cardova | Director of Legal & Secretary | — | male |
| Juan Marco Sparvieri | Chief Executive Officer | — | male |
| Rodrigo Alonso Herrera Aspra | Founder & Chairman of the Board | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LABB.MX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
